Form 4 for CYTK CYTOKINETICS INC
Accepted 2022-10-13 00:00:00 ET · period of report 2022-10-13 · accession 0001127602-22-023927 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-13 | 2022-10-13 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $9.65 | +21.5K | 189.9K | +13% | +$207.6K |
| D | 2022-10-13 | 2022-10-13 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $47.28 | -21.5K | 168.3K | -11% | -$1.02M |
| D | 2022-10-13 | 2022-10-13 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $0.00 | -21.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-13 | M | A | 21,513 | $9.65 | 189,859 | D | — | — | |
| 2 | Common | Common Stock | 2022-10-13 | S | D | 21,513 | $47.28 | 168,346 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2022-10-13 | M | D | 21,513 | $0.00 | 0 | D | $9.65 · 2014-03-24 to 2024-02-24 | 21,513 Common Stock |